跳至主要内容
临床试验/CTRI/2024/10/075949
CTRI/2024/10/075949尚未招募1/2 期

A comparative clinical study of sharpunkha moola churna and bhumyamlaki churna in the management of Asrigdara

Shri khudadad dungaji government ayurved hospital1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2024年11月15日最近更新:
适应症
相关药物

试验速览

阶段
1/2 期
状态
尚未招募
发起方
入组人数
60
试验地点
1
主要终点
Will reduce the symptoms of Asrigdara like excessive menstrual bleeding, weakness, Anemia due to excessive menstrual bleeding, body aches , will cure general weakness

研究概览

简要总结

In Ayurvedic textbooks, any irregularity in the menstrual cycle that results in heavy and prolonged uterine bleeding is refered to as Asrigdara. Asrigdara is a common gynaecological problem that mimics the dysfunctional form of abnormal uterine bleeding (AUB).

Acharya Sushruta has stated it as Pitta yukta Apan vayu, while Acharya Charaka has stated Asrigdara as Pitta Avrit Apan vayu and Rakhta Pradoshaj vikara.

Keeping all the above mentioned things in mind, due to the need of accessible, cheap and effective treatment for the disease, I have selected the subject of therapeutic and comparative study of Sharapunkha root powder and Bhumyamlaki churna in Asrigdara disease (Menorrhagia), which has been mentioned in Bhaishajya Ratnavali Pradara Chikitsa.

研究设计

研究类型
Interventional
分配方式
Randomized
盲法
None

入排标准

年龄范围
18.00 Year(s) 至 45.00 Year(s)(—)
性别
Female

入选标准

  • •Patients having clinical picture of Asrigdara Roga, DUB, Menorrhagia and polymenorrhagia.
  • •Heavy menstrual bleeding with or without regularity of cycle.
  • •The patient having problem of heavy menstrual bleeding for atleast 2 consecutive cycles.
  • •Patients who are prepared to provide consent and patient will be selected irrespective to religion / habitation.

排除标准

  • •Hb % less than 8gms.
  • •Pregnancy and IUCD insertion cases.
  • •Patient suffering from severe systemic uncompensatory disease of Heart/Liver/Kidney etc.
  • •Patient having malignancies.
  • •Patient suffering from uncontrolled DM, HTN.
  • •Patient suffering from uncontrolled endocrinopathy.
  • •Patient suffering from STDs, HIV, HBsAG etc.
  • •Patient suffering from endometrial tuberculosis.
  • •Patient suffering from coagulation disorder.
  • •Patient having bleeding due to miscarriage or abortion.

结局指标

主要结局

Will reduce the symptoms of Asrigdara like excessive menstrual bleeding, weakness, Anemia due to excessive menstrual bleeding, body aches , will cure general weakness

时间窗: 90 days

次要结局

  • Will reduce the symptoms of Asrigdara like excessive menstrual bleeding, weakness, Anemia due to excessive menstrual bleeding, body aches , will cure general weakness(90days)

研究者

发起方
Shri khudadad dungaji government ayurved hospital
申办方类型
Government medical college
责任方
Principal Investigator
主要研究者

Dr Chandrakant Shriwas

Shri Narayan Prasad Awasthi Goverment Ayurved College Raipur

研究点 (1)

Loading locations...

相似试验